(a) If the FFD program follows splitspecimen procedures, as described in §26.113, the licensee testing facility shall analyze aliquots of the specimen for the licensee’s or other entity’s purposes as described in this part. Except as provided in paragraph (b) in this section, the licensee testing facility shall store Bottles A and B of the specimen in a secure manner until the facility has finished testing. If the initial validity and drug test results are negative and the specimen in Bottle A will not be forwarded to the HHS-certified laboratory, the licensee testing facility may discard both Bottle A and Bottle B. If any test results are positive or indicate that the specimen is of questionable validity, the licensee testing facility shall forward Bottle A to the HHScertified laboratory for testing and shall retain Bottle B in secure storage, under the requirements of §26.159(i), or may forward it to the HHS-certified laboratory for storage.
CFR 10-26.135-2014由US-CFR-file 发布于 2014-11-10,并于 2014-11-10 实施。
CFR 10-26.135-2014 在中国标准分类中归属于: F00 标准化、质量管理。
非常抱歉,我们暂时无法提供预览,您可以试试: 免费下载 CFR 10-26.135-2014 前三页,或者稍后再访问。
点击下载后,生成下载文件时间比较长,请耐心等待......
Copyright ©2007-2022 ANTPEDIA, All Rights Reserved
京ICP备07018254号 京公网安备1101085018 电信与信息服务业务经营许可证:京ICP证110310号